Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo (Q39366450)

11 September 2017

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo (English)

1 reference

11 September 2017

neoplastic stem cells

1 reference

1 reference

Yuanxi Zhu

1

1 reference

11 September 2017

Xiaobei Zhang

2

1 reference

11 September 2017

Yan Liu

3

1 reference

11 September 2017

Sheng Zhang

4

1 reference

11 September 2017

Jingjing Liu

5

1 reference

11 September 2017

Yi Ma

6

1 reference

11 September 2017

Jin Zhang

7

1 reference

11 September 2017

11 April 2012

1 reference

11 September 2017

1 reference

11 September 2017

33

1 reference

11 September 2017

5

1 reference

11 September 2017

1349-1362

1 reference

https://scigraph.springernature.com/pub.10.1007/s13277-012-0383-6

11 September 2017

0 references

cites work

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

TOR, a central controller of cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

mTOR pathway and mTOR inhibitors as agents for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Targeting the molecular target of rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Radiation resistance and stem-like cells in brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

let-7 regulates self renewal and tumorigenicity of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Targeting mTOR pathway: A new concept in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Determinants of rapamycin sensitivity in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Inhibitor hijacking of Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Inhibition of protein kinase B/Akt. implications for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-012-0383-6

Headway in resistance to endocrine therapy in breast cancer

21 January 2018

1 reference

12 December 2020

Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium

1 reference

12 December 2020

The role of survivin in diagnosis, prognosis and treatment of breast cancer

1 reference

12 December 2020

Cancer stem cells persist in many cancer cell lines

1 reference

12 December 2020

10.1007/S13277-012-0383-6

Identifiers

DOI

1 reference

11 September 2017

1 reference